The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1630
August 9, 2021
View Complete Issue         Table of Contents 2019 
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
August 9, 2021 (Issue: 1630)
Myfembree (Myovant/Pfizer), an oral fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix, the estrogen estradiol, and the progestin norethindrone acetate, has been approved by the FDA for management...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
Article code: 1630b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.